Search
for
Sort by
Research 121–150 of 1000+
- Low-Molecular-Weight Synthetic Antioxidants: Classification, Pharmacological Profile, Effectiveness and Trends
- Pharmacological activities of Abrus precatorius Linn.: A comprehensive review of its ethnomedicinal uses and phytochemical profile.
- Randomized, double‐blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair
- Pharmacological activities of Abrus precatorius Linn.: A comprehensive review of its ethnomedicinal uses and phytochemical profile.
- 5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety
- Multi-target evaluation of Korean herbal compounds against the SRD5A2 / AR / beta-catenin axis for androgenetic alopecia: Boltz-2 cofold, ChEMBL-anchored ranking, ADMET-AI 107-endpoint safety panel, and pilosebaceous single-cell atlas-constrained prioritization of Saponin Re, Emodin, and Biochanin A
- Multi-target evaluation of Korean herbal compounds against the SRD5A2 / AR / beta-catenin axis for androgenetic alopecia: Boltz-2 cofold, ChEMBL-anchored ranking, ADMET-AI 107-endpoint safety panel, and pilosebaceous single-cell atlas-constrained prioritization of Saponin Re, Emodin, and Biochanin A
- New Treatments for Adult Female Acne
- Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
- Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.
- Photobiomodulation therapy for androgenetic alopecia: A clinician’s guide to home-use devices cleared by the Federal Drug Administration
- CARDIOVASCULAR SAFETY OF LOW-DOSE ORAL MINOXIDIL FOR ANDROGENETIC ALOPECIA IN PATIENTS WITH HYPERTENSION OR ARRHYTHMIAS
- Adverse effects of baricitinib in comparison to methotrexate in the treatment of severe alopecia areata
- Safety and efficacy of tavaborole (AN2690), a novel boron-based molecule, in 3 phase II trials for the topical treatment of toenail onychomycosis
- Precision and Personalized Medicine in Transdermal Drug Delivery Systems: Integrating AI Approaches
- Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- TERAPIA ORAL OU TÓPICA? REVISÃO INTEGRATIVA SOBRE O USO DE MINOXIDIL NA ALOPECIA ANDROGENÉTICA
- Safety and Efficacy of Minoxidil Treatment in Scarring Alopecia: A Scoping Review.
- Safety and tolerability of low-dose oral minoxidil in adolescents: A retrospective review
- The safety of 52 weeks of oral DHEA therapy for postmenopausal women
- GC–MS profiling and in silico prediction of MAPK receptor activation by fatty acids of watercress oil for hair growth marketed in Saudi Arabia
- Biological Profile of Cortexolone 17a-Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- Drug safety evaluation of exemestane
- 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure
- Supplementary Material for: Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
- Efficacy and safety of low-dose oral minoxidil in the management of androgenetic alopecia
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata